Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of a Bowel Cleansing Preparation (BLI800) in Pediatric Subjects Undergoing Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female between the ages of 12 to 16 (inclusive)~2. Undergoing colonoscopy for routinely accepted indications, including (but not limited to):~   * Subjected inflammatory bowel disease (IBD) or IBD follow-up~  * Lower gastrointestinal bleeding~  * Suspected colitis (allergic or other)~  * Abdominal pain~  * Chronic diarrhea~  * Cancer surveillance~  * Anemia of unknown etiology~  * Abnormal endosonography or manometry~  * Evaluation of barium enema results~3. If female, and of child-bearing potential, subject must use an acceptable form of birth control or remain abstinent for the duration of the study.~4. Negative pregnancy test at screening, if applicable~5. In the Investigator's judgment, caregiver is mentally competent to provide informed consent for their child to participate in the study.~Exclusion Criteria:~1. Subjects with known or suspected ileus, impaction, severe ulcerative colitis, acute peritonitis, gastrointestinal obstruction, gastric retention (gastroparesis), bowel perforation, toxic colitis or megacolon.~2. Subjects who had previous significant gastrointestinal surgeries.~3. Subjects with increased risk of bowel perforation, including connective tissue disorders, toxic dilation of the bowel or recent bowel surgery.~4. Subjects with uncontrolled pre-existing electrolyte abnormalities, or those with clinically significant electrolyte abnormalities based on Visit 1 laboratory results, such as hypernatremia, hyponatremia, hyperphosphatemia, hypokalemia, hypocalcemia, uncorrected dehydration, or those secondary to the use of diuretics or angiotensin converting enzyme (ACE) inhibitors.~5. Subjects with bleeding disorders and/or impaired platelet function, or neutropenia.~6. Subjects with a prior history of renal, liver or cardiac insufficiency (including congestive heart failure or other significant cardiac abnormality)~7. Subjects with estimated glomerular filtration rate (GFR) below normal range (less than 70 ml/min/1.73m2)~8. Subjects required to take any other oral medication within 3 hours of dosing until completion of both doses.~9. Subjects with impaired consciousness that predisposes them to pulmonary aspiration.~10. Subjects with tendency for nausea and/or vomiting, or that have known swallowing disorders.~11. Subjects for whom intake of substances is likely to affect gastrointestinal motility or urinary flow rate.~12. Subjects undergoing colonoscopy for foreign body removal and/or decompression.~13. Subjects with an abnormal ECG result at Visit 1.~14. Subjects who are pregnant or lactating, or intending to become pregnant during the study.~15. Subjects of childbearing potential who refuse a pregnancy test.~16. Subjects with a history of hypersensitivity to any preparation components.~17. Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures and history of major medical/psychiatric conditions that would compromise the safety of the study.~18. Subjects who have participated in an investigational surgical, drug, or device study within the past 30 days.~19. Subjects who withdraw consent before completion of Visit 1 procedures.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- BLI800 high dose (Type: EXPERIMENTAL): BLI800 bowel preparation (high dose)
- BLI800 low dose (Type: EXPERIMENTAL): BLI800 bowel preparation (low dose)
- PEG-ELS (Type: ACTIVE_COMPARATOR): PEG based bowel preparation

Based on this trial design, predict the completion outcome and termination type (if applicable).